JP2005530784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530784A5 JP2005530784A5 JP2004505051A JP2004505051A JP2005530784A5 JP 2005530784 A5 JP2005530784 A5 JP 2005530784A5 JP 2004505051 A JP2004505051 A JP 2004505051A JP 2004505051 A JP2004505051 A JP 2004505051A JP 2005530784 A5 JP2005530784 A5 JP 2005530784A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- day
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 12
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 229960000390 fludarabine Drugs 0.000 claims 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 102100031939 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims 1
- 229960002594 arsenic trioxide Drugs 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 238000001815 biotherapy Methods 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 238000011443 conventional therapy Methods 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- -1 doxetaxol Chemical compound 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 claims 1
- 229960000435 oblimersen Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960001476 pentoxifylline Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38084202P | 2002-05-17 | 2002-05-17 | |
| US42460002P | 2002-11-06 | 2002-11-06 | |
| PCT/US2003/015470 WO2003097052A2 (en) | 2002-05-17 | 2003-05-16 | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006288966A Division JP2007008966A (ja) | 2002-05-17 | 2006-10-24 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116363A Division JP2009191072A (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116367A Division JP5839770B2 (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530784A JP2005530784A (ja) | 2005-10-13 |
| JP2005530784A5 true JP2005530784A5 (OSRAM) | 2006-12-14 |
Family
ID=29553516
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505051A Pending JP2005530784A (ja) | 2002-05-17 | 2003-05-16 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2006288966A Pending JP2007008966A (ja) | 2002-05-17 | 2006-10-24 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116363A Withdrawn JP2009191072A (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116367A Expired - Lifetime JP5839770B2 (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2012273326A Expired - Lifetime JP5830005B2 (ja) | 2002-05-17 | 2012-12-14 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2013038222A Withdrawn JP2013126999A (ja) | 2002-05-17 | 2013-02-28 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2015125342A Expired - Lifetime JP6194335B2 (ja) | 2002-05-17 | 2015-06-23 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2017095838A Pending JP2017132817A (ja) | 2002-05-17 | 2017-05-12 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006288966A Pending JP2007008966A (ja) | 2002-05-17 | 2006-10-24 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116363A Withdrawn JP2009191072A (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2009116367A Expired - Lifetime JP5839770B2 (ja) | 2002-05-17 | 2009-05-13 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2012273326A Expired - Lifetime JP5830005B2 (ja) | 2002-05-17 | 2012-12-14 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2013038222A Withdrawn JP2013126999A (ja) | 2002-05-17 | 2013-02-28 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2015125342A Expired - Lifetime JP6194335B2 (ja) | 2002-05-17 | 2015-06-23 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
| JP2017095838A Pending JP2017132817A (ja) | 2002-05-17 | 2017-05-12 | 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物 |
Country Status (19)
| Country | Link |
|---|---|
| EP (9) | EP2316455A1 (OSRAM) |
| JP (8) | JP2005530784A (OSRAM) |
| KR (2) | KR100793564B1 (OSRAM) |
| CN (13) | CN1697655B (OSRAM) |
| AT (1) | ATE459357T1 (OSRAM) |
| AU (1) | AU2003234626B2 (OSRAM) |
| CA (10) | CA2672000C (OSRAM) |
| CY (3) | CY1110013T1 (OSRAM) |
| DE (1) | DE60331537D1 (OSRAM) |
| DK (1) | DK1505973T3 (OSRAM) |
| ES (2) | ES2521672T3 (OSRAM) |
| IL (9) | IL165254A0 (OSRAM) |
| LU (1) | LU92642I2 (OSRAM) |
| MX (1) | MXPA04011311A (OSRAM) |
| NZ (5) | NZ584663A (OSRAM) |
| PT (2) | PT2105135E (OSRAM) |
| SI (1) | SI1505973T1 (OSRAM) |
| WO (1) | WO2003097052A2 (OSRAM) |
| ZA (3) | ZA200503656B (OSRAM) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| WO2002068414A2 (en) | 2001-02-27 | 2002-09-06 | The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| CA2672000C (en) * | 2002-05-17 | 2011-11-29 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| JP2006508950A (ja) * | 2002-10-31 | 2006-03-16 | セルジーン・コーポレーション | 黄斑変性の治療用組成物 |
| US7785601B2 (en) * | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| WO2005016326A2 (en) * | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| SG133603A1 (en) | 2003-09-17 | 2007-07-30 | Us Gov Health & Human Serv | Thalidomide analogs as tnf-alpha modulators |
| US8952895B2 (en) | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| KR20120039065A (ko) * | 2003-12-02 | 2012-04-24 | 셀진 코포레이션 | 혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물 |
| US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| EP1727529B1 (en) | 2004-03-17 | 2016-03-02 | Lars Michael Larsen | Prevention of retinopathy by inhibition of the visual cycle |
| BRPI0509019A (pt) * | 2004-03-22 | 2007-08-07 | Celgene Corp | métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit |
| CA2562715A1 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
| CN101098694A (zh) * | 2004-11-12 | 2008-01-02 | 细胞基因公司 | 使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物 |
| BRPI0518282A2 (pt) * | 2004-11-23 | 2008-11-11 | Celgene Corp | uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio |
| US8715677B2 (en) * | 2005-09-01 | 2014-05-06 | Celgene Corporation | Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy |
| JP5984324B2 (ja) * | 2005-12-01 | 2016-09-06 | メディカル プログノシス インスティテュート エー／エス | 治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用 |
| WO2007120669A1 (en) | 2006-04-13 | 2007-10-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Tetrahalogenated compounds useful as inhibitors of angiogenesis |
| RU2426542C2 (ru) * | 2006-05-26 | 2011-08-20 | Селджин Корпорейшн | Способы и композиции с применением иммуномодулирующих соединений при комбинированном лечении |
| CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| EP2641601B8 (en) * | 2006-08-07 | 2016-09-21 | AbbVie Biotherapeutics Inc. | Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezomib |
| CA2665778A1 (en) * | 2006-10-19 | 2008-05-15 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases |
| RU2348420C2 (ru) * | 2007-04-17 | 2009-03-10 | ФГУ Ростовский научно-исследовательский онкологический институт Росздрава | Способ лечения местно-распространенного рака легкого |
| CA2700617C (en) * | 2007-09-28 | 2018-11-06 | Celgene Cellular Therapeutics | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| UA104579C2 (uk) | 2007-12-10 | 2014-02-25 | Байокрист Фармасьютикалз, Инк. | Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом |
| CN101977603A (zh) * | 2008-01-29 | 2011-02-16 | 细胞基因公司 | 使用免疫调节化合物来调节cd59水平的方法 |
| RU2398525C1 (ru) * | 2009-03-25 | 2010-09-10 | Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" | Способ лечения рака легкого |
| CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
| WO2011066351A1 (en) * | 2009-11-24 | 2011-06-03 | Celgene Corporation | Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells |
| RS56232B1 (sr) | 2010-02-11 | 2017-11-30 | Celgene Corp | Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene |
| EP2544687A1 (en) * | 2010-03-12 | 2013-01-16 | Celgene Corporation | Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| US20120045435A1 (en) * | 2010-08-18 | 2012-02-23 | Theresa Deisher | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| EP2637653B1 (en) * | 2010-11-11 | 2018-01-10 | Ingo Schmidt-Wolf | Compositions comprising ethacrynic acid and lenalidomide and/or thalidomide for use in treating myeloma |
| US8927725B2 (en) | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
| WO2014039960A1 (en) * | 2012-09-10 | 2014-03-13 | Celgene Corporation | Methods for the treatment of locally advanced breast cancer |
| US9839632B2 (en) * | 2013-04-02 | 2017-12-12 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| GB201322626D0 (en) * | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| CN104231068A (zh) * | 2014-01-27 | 2014-12-24 | 苏州发士达生物科技有限公司 | 人白细胞介素ii突变体及其应用 |
| JP6616934B2 (ja) * | 2014-05-22 | 2019-12-04 | 株式会社 資生堂 | レナリドミドの光学分割方法 |
| EP3925609B1 (en) | 2014-08-22 | 2025-07-30 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| WO2016046640A2 (en) | 2014-09-26 | 2016-03-31 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| WO2016116854A1 (en) * | 2015-01-20 | 2016-07-28 | Raghavan Sreevatsan | Self-illuminating cheek retractor |
| AU2016255577A1 (en) | 2015-04-30 | 2018-11-15 | Nant Holdings Ip, Llc | Patient treatment via teratogenic pharmaceutical compounds |
| PL3313528T3 (pl) * | 2015-06-29 | 2021-12-13 | Bristol-Myers Squibb Company | Schematy dawkowania immunoterapeutycznego obejmujące pomalidomid i przeciwciało anty-cs1 w leczeniu raka |
| IL258701B2 (en) * | 2015-10-21 | 2024-07-01 | Teclison Ltd | Preparations and methods for curing cancer with immune support |
| CN105388237B (zh) * | 2015-12-28 | 2017-02-01 | 成都百裕金阁莱药业有限公司 | 阿普斯特中3‑乙酰氨基邻苯二甲酸的检测方法 |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| CA3050309A1 (en) | 2017-01-31 | 2018-08-09 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| SG11201907744QA (en) | 2017-04-01 | 2019-09-27 | Avm Biotechnology Llc | Replacement of cytotoxic preconditioning before cellular immunotherapy |
| MX2019014023A (es) | 2017-05-24 | 2020-02-17 | Novartis Ag | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer. |
| EP3700508A1 (en) * | 2017-10-26 | 2020-09-02 | Synbias Pharma AG | Lenalidomide immediate release formulations |
| US11358952B2 (en) | 2018-04-23 | 2022-06-14 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith |
| WO2019226770A1 (en) * | 2018-05-23 | 2019-11-28 | Celgene Corporation | Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile |
| CN112689627B (zh) * | 2018-09-07 | 2022-03-29 | 南京明德新药研发有限公司 | 三环取代哌啶二酮类化合物 |
| EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| US20240216354A1 (en) * | 2019-10-04 | 2024-07-04 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory imide drugs as zeta-chain-associated protein kinase 70 (zap70) agonists and uses thereof |
| HRP20231487T1 (hr) * | 2019-10-21 | 2024-03-01 | Celgene Corporation | Postupci za liječenje hematoloških malignosti uporabom 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-diona |
| EP4048668A4 (en) * | 2019-10-21 | 2024-03-13 | Celgene Corporation | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| CR20220353A (es) | 2019-12-19 | 2022-10-20 | Arvinas Operations Inc | Compuestos y métodos para la degradación dirigida del receptor de andrógenos |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3228601A (en) | 1964-02-20 | 1966-01-11 | Monarch Marking Systems Inc | Controls for marking machine |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US6114355A (en) | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| DE69717831T3 (de) | 1996-07-24 | 2018-08-30 | Celgene Corp. | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| ATE418536T1 (de) | 1996-08-12 | 2009-01-15 | Celgene Corp | Neue immunotherapeutische mittel und deren verwendung in der reduzierung von cytokinenspiegel |
| DE69734290T2 (de) * | 1996-11-05 | 2006-07-06 | The Children's Medical Center Corp., Boston | Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid |
| US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| EP1985285A3 (en) * | 1999-04-01 | 2009-08-12 | Hana Biosciences, Inc. | Compositions and methods for treating lymphoma |
| CN1429121A (zh) * | 2000-03-17 | 2003-07-09 | 细胞治疗公司 | 聚谷氨酸－喜树碱结合物及其制备方法 |
| ATE322266T1 (de) * | 2000-05-15 | 2006-04-15 | Celgene Corp | Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten |
| US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| ATE374609T1 (de) * | 2000-11-30 | 2007-10-15 | Childrens Medical Center | Synthese von 4-aminothalidomid enantiomeren |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| CA2672000C (en) * | 2002-05-17 | 2011-11-29 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
-
2003
- 2003-05-16 CA CA2672000A patent/CA2672000C/en not_active Expired - Lifetime
- 2003-05-16 CA CA2727830A patent/CA2727830C/en not_active Expired - Lifetime
- 2003-05-16 NZ NZ584663A patent/NZ584663A/en not_active IP Right Cessation
- 2003-05-16 SI SI200331793T patent/SI1505973T1/sl unknown
- 2003-05-16 CA CA2794060A patent/CA2794060C/en not_active Expired - Lifetime
- 2003-05-16 DK DK03728969.1T patent/DK1505973T3/da active
- 2003-05-16 EP EP10185504A patent/EP2316455A1/en not_active Withdrawn
- 2003-05-16 CA CA2752127A patent/CA2752127A1/en not_active Abandoned
- 2003-05-16 EP EP09004756A patent/EP2087891A3/en not_active Withdrawn
- 2003-05-16 CN CN038168995A patent/CN1697655B/zh not_active Expired - Lifetime
- 2003-05-16 CA CA2794297A patent/CA2794297A1/en not_active Abandoned
- 2003-05-16 CN CN201310343756.1A patent/CN103495169B/zh not_active Expired - Lifetime
- 2003-05-16 KR KR1020047018587A patent/KR100793564B1/ko not_active Expired - Lifetime
- 2003-05-16 CN CN201110257161.5A patent/CN102342938B/zh not_active Expired - Lifetime
- 2003-05-16 EP EP10177041A patent/EP2272512A1/en not_active Withdrawn
- 2003-05-16 ES ES09008756.0T patent/ES2521672T3/es not_active Expired - Lifetime
- 2003-05-16 WO PCT/US2003/015470 patent/WO2003097052A2/en not_active Ceased
- 2003-05-16 CA CA2476983A patent/CA2476983C/en not_active Expired - Lifetime
- 2003-05-16 JP JP2004505051A patent/JP2005530784A/ja active Pending
- 2003-05-16 MX MXPA04011311A patent/MXPA04011311A/es active IP Right Grant
- 2003-05-16 NZ NZ536907A patent/NZ536907A/en not_active IP Right Cessation
- 2003-05-16 PT PT90087560T patent/PT2105135E/pt unknown
- 2003-05-16 CA CA2752140A patent/CA2752140A1/en not_active Abandoned
- 2003-05-16 AU AU2003234626A patent/AU2003234626B2/en not_active Expired
- 2003-05-16 CN CN201110256752.0A patent/CN102379874B/zh not_active Expired - Lifetime
- 2003-05-16 CA CA2727824A patent/CA2727824A1/en not_active Abandoned
- 2003-05-16 CN CN2011102561581A patent/CN102335173A/zh active Pending
- 2003-05-16 EP EP12158938.6A patent/EP2561874A3/en not_active Withdrawn
- 2003-05-16 PT PT03728969T patent/PT1505973E/pt unknown
- 2003-05-16 KR KR1020067020849A patent/KR100822149B1/ko not_active Expired - Fee Related
- 2003-05-16 CN CN201310344609.6A patent/CN103494817A/zh not_active Withdrawn
- 2003-05-16 CA CA2752122A patent/CA2752122A1/en not_active Abandoned
- 2003-05-16 CN CN2006101504843A patent/CN1981761B/zh not_active Expired - Fee Related
- 2003-05-16 EP EP14189022.8A patent/EP2915533B1/en not_active Revoked
- 2003-05-16 NZ NZ549175A patent/NZ549175A/en not_active IP Right Cessation
- 2003-05-16 IL IL16525403A patent/IL165254A0/xx unknown
- 2003-05-16 NZ NZ563281A patent/NZ563281A/en not_active IP Right Cessation
- 2003-05-16 EP EP09008756.0A patent/EP2105135B1/en not_active Revoked
- 2003-05-16 CA CA2752124A patent/CA2752124A1/en not_active Abandoned
- 2003-05-16 EP EP10177056A patent/EP2272513A1/en not_active Withdrawn
- 2003-05-16 CN CN201410690665.XA patent/CN104606193A/zh not_active Withdrawn
- 2003-05-16 DE DE60331537T patent/DE60331537D1/de not_active Expired - Lifetime
- 2003-05-16 CN CN2011102571780A patent/CN102429908A/zh active Pending
- 2003-05-16 NZ NZ572388A patent/NZ572388A/en not_active IP Right Cessation
- 2003-05-16 CN CN201310344594.3A patent/CN103393681B/zh not_active Expired - Lifetime
- 2003-05-16 EP EP03728969A patent/EP1505973B1/en not_active Revoked
- 2003-05-16 EP EP09008775A patent/EP2105136A3/en not_active Withdrawn
- 2003-05-16 AT AT03728969T patent/ATE459357T1/de active
- 2003-05-16 CN CN2011102566053A patent/CN102302494A/zh active Pending
- 2003-05-16 ES ES03728969T patent/ES2340027T3/es not_active Expired - Lifetime
- 2003-05-16 CN CN2013103449770A patent/CN103393695A/zh not_active Withdrawn
- 2003-11-06 ZA ZA200503656A patent/ZA200503656B/xx unknown
- 2003-11-06 CN CNA2003801083980A patent/CN1735415A/zh active Pending
-
2004
- 2004-11-16 IL IL165254A patent/IL165254A/en active IP Right Grant
- 2004-11-22 ZA ZA200409388A patent/ZA200409388B/xx unknown
- 2004-11-22 ZA ZA200409387A patent/ZA200409387B/en unknown
-
2006
- 2006-10-19 IL IL178746A patent/IL178746A0/en unknown
- 2006-10-19 IL IL178748A patent/IL178748A/en active IP Right Grant
- 2006-10-19 IL IL178745A patent/IL178745A/en active Protection Beyond IP Right Term
- 2006-10-19 IL IL178747A patent/IL178747A/en active IP Right Grant
- 2006-10-24 JP JP2006288966A patent/JP2007008966A/ja active Pending
-
2009
- 2009-05-13 JP JP2009116363A patent/JP2009191072A/ja not_active Withdrawn
- 2009-05-13 JP JP2009116367A patent/JP5839770B2/ja not_active Expired - Lifetime
- 2009-05-26 IL IL198978A patent/IL198978A/en active IP Right Grant
-
2010
- 2010-04-23 CY CY20101100363T patent/CY1110013T1/el unknown
-
2012
- 2012-05-10 IL IL219732A patent/IL219732A0/en unknown
- 2012-12-14 JP JP2012273326A patent/JP5830005B2/ja not_active Expired - Lifetime
-
2013
- 2013-02-28 JP JP2013038222A patent/JP2013126999A/ja not_active Withdrawn
-
2014
- 2014-11-27 CY CY20141100987T patent/CY1115782T1/el unknown
-
2015
- 2015-01-27 LU LU92642C patent/LU92642I2/xx unknown
- 2015-02-06 CY CY2015003C patent/CY2015003I1/el unknown
- 2015-06-23 JP JP2015125342A patent/JP6194335B2/ja not_active Expired - Lifetime
-
2016
- 2016-03-22 IL IL244727A patent/IL244727A0/en unknown
-
2017
- 2017-05-12 JP JP2017095838A patent/JP2017132817A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005530784A5 (OSRAM) | ||
| JP2006507271A5 (OSRAM) | ||
| IL168061A (en) | 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)- piperidine- 2, 6-dione for use in a medicament for treating and managing myelodysplastic syndromes | |
| JP2020172502A5 (OSRAM) | ||
| CA2672000A1 (en) | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma | |
| JP2007045839A5 (OSRAM) | ||
| JP2009510171A5 (OSRAM) | ||
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| JP2009545600A5 (OSRAM) | ||
| RU2316553C2 (ru) | Производные пиперидина, фармацевтическая композиция на их основе и применение | |
| CA2528784A1 (en) | Hexahydropyridoisoquinolines as dpp-iv inhibitors | |
| FI3651766T3 (fi) | 4-(4-(4-(((2-(2,6-dioksopiperidin-3-yyli)-l-oksoisoindolin-4-yyli)oksi)metyyli)bentsyyli)piperatsin-1-yyli)-3-fluoribentsonitriili antiproliferatiivisena yhdisteenä | |
| HRP20100664T1 (hr) | Upotreba 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-diona u lijecenju limfoma stanica plasta | |
| JP2017515802A5 (OSRAM) | ||
| JP2001522833A5 (OSRAM) | ||
| RU2008117432A (ru) | Способы применения 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил)пиперидин-2,6-диона для лечения определенных типов лейкоза | |
| JP2009529544A5 (OSRAM) | ||
| EP2698158A1 (en) | Immunomodulation by IAP Inhibitors | |
| JP2004536790A5 (OSRAM) | ||
| JP2004534788A5 (OSRAM) | ||
| EP1345604B1 (en) | Use of a alpha-halogen-acryloyl distamycin derivate for the preparation of a medicament for the treatment of cancer | |
| JP2005538184A5 (OSRAM) | ||
| US20080207644A1 (en) | Therapeutic materials and methods | |
| JP2021107447A5 (OSRAM) | ||
| TW200517127A (en) | Novel composition |